邯郸月经之后不干净(邯郸怀孕几周照四维彩超比较好) (今日更新中)

WASHINGTON, April 11 (Xinhua) -- Taking a statin before having major elective surgery reduces potentially serious kidney complications, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.Each year, more than 230 million major elective surgeries are performed around the world. Unfortunately, many patients who undergo major operations develop kidney injury soon after surgery, often due to decreased blood flow to the kidneys and/or the effects of inflammation.Animal studies suggest that the cholesterol-lowering drugs called statins protect the kidneys from such damage, but whether a similar benefit occurs in humans is uncertain. To investigate, Amber Molnar, University of Western Ontario, and colleagues conducted a population-based retrospective study of all older patients who underwent major elective surgery in the province of Ontario, Canada from 1995 to 2008. Surgeries included cardiac, thoracic, vascular, intra-abdominal, and retroperitoneal procedures.A total of 213,347 patients from 211 hospitals underwent major elective surgery, and 4,020 patients (1.9 percent) developed postoperative kidney injury within two weeks of surgery. A total of 1,173 patients (0.5 percent) required dialysis within two weeks of surgery, and 5,974 patients (2.8 percent) died within a month of surgery.Prior to surgery, 67,941 patients (32 percent) were taking a statin. Patients taking a statin were 20 percent less likely to develop kidney injury, need dialysis, and die compared to patients who were not taking a statin. Also, there was evidence of a dose-effect, with patients on higher potency statins having less kidney injury. In addition, statins were beneficial whether they were started greater than 90 days or less than 30 days prior to surgery."Our study suggests that statin use in older persons results in less kidney injury following major elective surgery and reduces the risk of premature death after surgery," said Molnar, adding that the results warrant further investigation with more rigorous studies, but such trials will be difficult to carry out.

Google chairman Eric Schmidt has promised that the firm will simplify the process by which Android phone users agree to share their data.It follows questions in the US Senate about how much location information is stored by mobile handsets.Speaking in the UK at a conference on privacy, he also revealed that Google plans to offer web users more control over their online profile.Mr Schmidt insisted that the company took the matter "very seriously".He told attendees at the Big Tent debate in Hertfordshire that his firm was working on "a series of projects" aimed at increasing transparency.Those include a revised Google Dashboard, where users can see what data they have shared with the search giant."It is worth stressing that we can only do this with data you have shared with Google. We can't be a vacuum-cleaner for the whole internet," he said.Mr Schmidt stressed that Google was on the side of consumers when it came to privacy. "In general we take the position that you own your data and should be able to opt in or out of a service," he said.But he added that if users gave consent for sharing data, it would help Google improve its services."If you choose to give us that information we can do a better job. If we know a little bit more about you we can offer better targeted search," he explained.Super injunctions revealed A recent hearing in the US Senate quizzed Google on the amount of data stored on Android handsets. The company argued that it allows people to opt out of location-based services.But Mr Schmidt conceded that the terms and conditions whereby users sign up to services needs to be simplified. "We intent to do that," he said.He predicted that such services would be more heavily regulated in the future.During a lively debate on the issue of privacy, it was revealed to the Big Tent audience, alongside several names of current super-injunction holders, that more data has been collected in the last seven years than in the whole of previous human history.

BEIJING, Jan. 25 (Xinhua) -- A book collecting speeches made by Chinese President Hu Jintao during his state visit to the United States earlier this month has been published by the People's Publishing House.The book was distributed by Xinhua Bookstores Tuesday.

LOS ANGELES, April 7 (Xinhua) -- Using NASA's Galaxy Evolution Explorer (GEE) satellite, U.S. astronomers are hunting for nearby, hard-to-see stars which could very well be home to the easiest-to-see alien planets, it was announced on Thursday.U.S. astronomers are ferreting out the new targets after the glare of bright, shining stars has frustrated most efforts at visualizing distant worlds, NASA's Jet Propulsion Laboratory (JPL) said.So far, only a handful of distant planets, or exoplanets, have been directly imaged. Small, newborn stars are less blinding, making the planets easier to see, but the fact that these stars are dim means they are hard to find in the first place."Fortunately, the young stars emit more ultraviolet light than their older counterparts, which makes them conspicuous to the ultraviolet-detecting GEE," JPL said in a press release."We've discovered a new technique of using ultraviolet light to search for young, low-mass stars near the Earth," said David Rodriguez, a graduate student of astronomy at University of Californian, Los Angeles. "These young stars make excellent targets for future direct imaging of exoplanets."Young stars, like human children, tend to be a bit unruly -- they spout a greater proportion of energetic X-rays and ultraviolet light than more mature stars. In some cases, X-ray surveys can pick out these youngsters due to the "racket" they cause. However, many smaller, less "noisy" baby stars perfect for exoplanet imaging studies have gone undetected except in the most detailed X-ray surveys. To date, such surveys have covered only a small percentage of the sky, according to JPL in Pasadena, Los Angeles.Rodriguez and his team figured that the GEE, which has scanned about three-quarters of the sky in ultraviolet light, could fill this gap.Astronomers compared readings from the telescope with optical and infrared data to look for the telltale signature of rambunctious junior stars. Follow-up observations of 24 candidates identified in this manner determined that 17 of the stars showed clear signs of youth, validating the team's approach, JPL said."The Galaxy Evolution Explorer can readily select young, low- mass stars that are too faint to turn up in all-sky X-ray surveys, which makes the telescope an incredibly useful tool," Rodriguez said in the release.

COPENHAGEN, April 30 (Xinhua) -- As traditional Chinese medicine (known as TCM in Europe) becomes increasingly popular worldwide and has gradually been regarded as a useful component to Western medical treatments, Denmark is no stranger to such trends.According to a study published by the University of Copenhagen in mid-Feb., up to one-third of Danish hospitals choose complementary or alternative therapies, including TCM methods, to treat pain, cancer, mental disease, tumors and infertility. Acupuncture remains the most widely-practiced form of these treatments, used in some 97 percent of the cases.The nationwide acceptance of acupuncture and massage therapists, the growing ranks of herbal practitioners, and the hosting of an annual pan-Scandinavian TCM conference since 2007, all underline the popularity of alternative medicine, including the TCM, in the country.However, the overall market presence of TCM, and herbal medicines in particular, is relatively small in Denmark and Europe at large. As many European policymakers insist that traditional herbal medicines "are neither scientifically documented nor tested according to Western requirements," these treatments face difficulties in obtaining licenses and boosting sales in Europe.In fact, despite their historical pedigree and widely-accepted efficacy, TCM products are often classified as "healthcare products" or "food," rather than "drugs" in European markets.A big challenge for TCM products to gain more access to the continent is the EU's Traditional Herbal Medicinal Products Directive, which stipulates that all such products must obtain authorization if they are to be sold within the EU, starting May 1, 2011.The directive says producers must prove the product in question has been used for 30 years, 15 of which within the EU, so as to ensure its safety.While licensing is expected to be onerous and expensive, Denmark has tried to bring TCM products into the Western medical mainstream from as early as 2005. The country's well-developed biochemical and medical industry, modernized agriculture and horticulture sectors and a strong track record of cooperative research in these fields, has helped TCM's cause.For instance, Traditional Complementary Medicine Denmark, a company helping herbal product makers market their goods in Western countries, uses modern biotechnology processes and clinical trials to scientifically verify and document the efficacy of existing herbal medicines.It also advises herbal product makers on how to align their standards with European requirements so as to acquire the necessary sales licenses. Sometimes, simple solutions like clearer and more detailed labeling of a TCM product's ingredients can help improve its marketability. Patent applications and drug approvals procedures must follow, before the product can access the EU pharmaceutical market, usually in pill form.Investing in herbal medicine also makes financial sense for Denmark, as it is encourages development of low-bulk, high-value agricultural products, which can be easily transported all over the globe.Development Centre Aarslev, a Danish agro-research body and partner of TCM Denmark, studies the active ingredients contained in medicinal plants and their impact on human health conditions such as cardiovascular problems, diabetes and allergies. One of the earliest collaborations it undertook with a producer of herbal medicine showed the effectiveness of extracts from the hips of the dog rose plant in treating rheumatoid arthritis.A spokesperson for the institution said, "We have documented analytical evidence which shows that arthritis patients can reduce their consumption of conventional anti-arthritis drugs by up to 50 percent, if they combine them with the herbal drug based on dog rose hips."Given Denmark's population of 5.5 million people, this could translate into savings of 200 million U.S. dollars a year on anti-arthritis medication, the spokesperson added.Other plant-based interventions could hold wider public health benefits. TCM practitioners say herbal medicines can improve blood circulation in humans, and contain naturally-occurring antioxidants which can reduce the risks of heart attacks and better regulate cardiovascular functions. This has potentially wide-ranging benefit for Western societies, where heart disease is a major threat.Heart disease was the most common cause of death in Denmark until 2000, and cardiovascular disease the commonest until 2008, with cancer now ranking the biggest killer.In fact, TCM herbal remedies are also considered a good choice for cancer treatment, as certain plants contain hormone-like substance which can influence hormone-dependent cancers, such as breast and prostate cancer.TCM supporters say the obvious benefit of such an intervention is the avoidance of more commonly-used chemotherapy and radiation treatments which often produce severe side-effects in patients. Relevant herbal therapies can help strengthen cancer patient's immune system, reduce side-effects of chemotherapy and radiation therapy, and alleviate other symptoms of the disease.Given the many potential benefits of TCM, the EU's tightening of rules may appear harsh. Still, TCM is considered a relatively novel approach to medicine in Europe. Moreover, the dominant market share and general clout of the chemical-based, Western pharmaceutical industry also makes it difficult for traditional remedies to stake their claim.

来源：资阳报